Profil
Fabrice Piu worked as a Director of Chemical Genomics at ACADIA Pharmaceuticals, Inc. and as a Vice President of Research & Preclinical Development at Otonomy, Inc. He holds a doctorate degree from École Normale Supérieure and undergraduate and graduate degrees from the University of Lyon.
Anciens postes connus de Fabrice Piu
| Sociétés | Poste | Fin |
|---|---|---|
| OTONOMY | Directeur Technique/Scientifique/R&D | 01/01/2023 |
| ACADIA PHARMACEUTICALS INC. | Corporate Officer/Principal | - |
Formation de Fabrice Piu
| École Normale Supérieure | Doctorate Degree |
| University of Lyon | Graduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| ACADIA PHARMACEUTICALS INC. | Health Technology |
| Entreprise privées | 1 |
|---|---|
Otonomy, Inc.
 Otonomy, Inc. BiotechnologyHealth Technology Otonomy, Inc. operates as a biopharmaceutical company. engages in the development of therapeutics for neurotology. The firm’s product pipeline includes OTIVIDEX (dexamethasone) Meniere's disease, OTIPRIO (ciprofloxacin otic suspension) acute otitis media with tubes (AOMT), OTO-313 (gacyclidine) tinnitus, OTO-413 (BDNF) hidden hearing Loss, OTO-510 (otoprotectant) prevent CIHL, OTO-6XX (hair cell regeneration) severe hearing loss. It operates under the Otiprio brand. The company was founded by Jay B. Lichter, Jeffrey Harris, Rick Friedman, and Allen F. Ryan on May 6, 2008 and is headquartered in San Diego, CA. | Health Technology |
